Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the EU / 2025-522207-15-01
Authorised, recruiting Phase I/II

An Open-label, Multicenter, Two Part, Ascending Dose Followed by a Controlled Trial to Assess the Safety and Efficacy of a Subretinal Administration of AAVB-039 in Participants with Stargardt Disease (STGD1) (CELESTE)

2025-522207-15-01 · tracked via the Priya Life Science EU tracker
Sponsor
Aavantgarde Bio S.r.l
Sponsor type
Pharmaceutical company
Therapeutic area
Eye Diseases
Decision date
10/04/2026
Enrollment target
21
Sites
Belgium, Italy, Netherlands, Norway

Condition studied

Stargardt Disease (STGD1)

Investigational medicinal product(s)

AAVB-039

Eligibility

Age group
18-64 years, 0-17 years
Sex
Female, Male

Primary endpoint

To measure the number and severity of treatment related adverse events following treatment with AAVB-039

Endpoint detail

Change in the area of atrophy (assessed via short wavelength fundus autofluorescence (SW-FAF), following treatment with AAVB-039., Change in ellipsoid zone (EZ) loss following treatment with AAVB-039., Change in macular sensitivity assessed via microperimetry following treatment with AAVB-039, Change in visual acuity following treatment with AAVB-039

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522207-15-01 on CTIS ↗ ← All trials in the EU